- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07540572
En studie for å undersøke sikkerheten, farmakokinetikken og foreløpig effekt av IDE574-terapi hos voksne deltakere med avanserte solide tumorer
An Open Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of IDE574 as Monotherapy in Locally Advanced or Metastatic Solid Tumors and as Combination Therapy With Fulvestrant in Locally Advanced or Metastatic Cancer
IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7.
The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants with locally advanced or metastatic solid tumors and as combination therapy with fulvestrant in participants with advanced or metastatic cancer.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Part 1 - Monotherapy Dose Escalation and Expansion:
Part 1A - Monotherapy Dose Escalation Part 1A will evaluate increasing doses of IDE574 to assess safety, tolerability and to determine dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD) or the recommended dose for expansion (RDE) in subjects with advanced or metastatic cancer.
Part 1B - Monotherapy Dose Expansion Part 1B will evaluate in ER+ HER2- advanced or metastatic cancer at one RDE determined from Part 1A or the MTD.
Part 1C - Exploratory Food Effect Sub-study
Part 2 - Combination Dose Escalation and Expansion
Part 2A - IDE574 Combination Therapy with Fulvestrant Dose Escalation Part 2A will evaluate participants with advanced or metastatic cancer with escalating doses of IDE574 in combination with fulvestrant to assess safety, tolerability and to determine DLTs, MTD or RDE.
Part 2B - IDE574 Combination Therapy with Fulvestrant Dose Expansion Part 2B will randomly assign participants with advanced or metastatic cancer to dose levels selected from Part 2A
Studietype
Registrering (Antatt)
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: IDEAYA Clinical Trials
- Telefonnummer: +1-855-433-224
- E-post: IDEAYAClinicalTrials@ideayabio.com
Studiesteder
-
-
California
-
Santa Monica, California, Forente stater, 90404-2095
- Aktiv, ikke rekrutterende
- UCLA - Parkside Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, Forente stater, 06510-3206
- Rekruttering
- Yale School of Medicine - Cedar Street
-
Hovedetterforsker:
- Patricia LoRusso, MD
-
Ta kontakt med:
- Karen Seely
- Telefonnummer: 203-314-3303
- E-post: karen.rodriguezvasquez@yale.edu
-
-
Florida
-
Plantation, Florida, Forente stater, 33322
- Rekruttering
- Florida Clinical Trials Group
-
Hovedetterforsker:
- Harshad Amin, MD
-
Ta kontakt med:
- Sandra Perez
- Telefonnummer: 772-297-3057
- E-post: perezs@floridactg.com
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322-1013
- Rekruttering
- Winship Cancer Institute, Emory University
-
Hovedetterforsker:
- Shipra Gandhi, MD
-
Ta kontakt med:
- Alejandra Bono
- Telefonnummer: 404-778-0954
- E-post: alejandra.maria.bono@emory.edu
-
-
Missouri
-
St Louis, Missouri, Forente stater, 63110-1010
- Rekruttering
- Washington University - Siteman Cancer Center
-
Hovedetterforsker:
- Faisal Fa'ak, MD
-
Ta kontakt med:
- Pamela Coe
- Telefonnummer: 314-747-7569
- E-post: mpamela@wustl.edu
-
-
New Jersey
-
East Brunswick, New Jersey, Forente stater, 08816
- Rekruttering
- START Astera, LLC
-
Hovedetterforsker:
- Bruno Fang, MD
-
Ta kontakt med:
- Bruno S Fang
- Telefonnummer: 732-426-4750
- E-post: info@startresearch.com
-
-
New York
-
Lake Success, New York, Forente stater, 11042
- Rekruttering
- START New York Long Island, LLC
-
Hovedetterforsker:
- Geraldine O'Sullivan Coyne, MD
-
Ta kontakt med:
- Geraldine O'Sullivan Coyne
- Telefonnummer: 363-207-5160
- E-post: g.osullivancoyne@startresearch.com
-
New York, New York, Forente stater, 10032-3729
- Aktiv, ikke rekrutterende
- Columbia University Medical Center -161 Fort Washington
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- SCRI Oncology Partners - PPDS
-
Hovedetterforsker:
- Sarah Premji, MD
-
Ta kontakt med:
- Connor Frost
- Telefonnummer: 615-478-3475
- E-post: connor.frost@scri.com
-
-
Texas
-
Austin, Texas, Forente stater, 78758
- Rekruttering
- NEXT Texas LLC - Austin
-
Hovedetterforsker:
- Sheena Sahota, MD
-
Ta kontakt med:
- Heather Watson
- Telefonnummer: 737-610-5202
- E-post: nxtaus_coordinators@nextoncology.com
-
Dallas, Texas, Forente stater, 75039
- Rekruttering
- NEXT Texas LLC - Dallas
-
Hovedetterforsker:
- Faran Polani, MD
-
Ta kontakt med:
- Carmen Gonzalez
- Telefonnummer: 210-580-9479
- E-post: NXTDFW_Coordinators@nextoncology.com
-
Fort Worth, Texas, Forente stater, 76104
- Rekruttering
- START Dallas Fort Worth, LLC
-
Hovedetterforsker:
- Henry Xiong, MD
-
Ta kontakt med:
- Henry Xiong
- Telefonnummer: 682-350-3010
- E-post: info@startresearch.com
-
Houston, Texas, Forente stater, 77030-4009
- Rekruttering
- MD Anderson Cancer Center
-
Hovedetterforsker:
- Timothy Yap, MD
-
Ta kontakt med:
- Desirae Dufner
- Telefonnummer: 713-524-3434
- E-post: DDufner@mdanderson.org
-
Houston, Texas, Forente stater, 77054
- Rekruttering
- NEXT Texas LLC - Houston
-
Hovedetterforsker:
- Jennifer Segar, MD
-
Ta kontakt med:
- Carmen Gonzalez
- Telefonnummer: 210-580-9479
- E-post: nxthou_coordinators@nextoncology.com
-
San Antonio, Texas, Forente stater, 78229
- Rekruttering
- NEXT Texas LLC - San Antonio
-
Hovedetterforsker:
- David Sommerhalder, MD
-
Ta kontakt med:
- April Guerra
- Telefonnummer: 210-580-9500
- E-post: NXTSA_Coordinators@nextoncology.com
-
San Antonio, Texas, Forente stater, 78229
- Rekruttering
- Start San Antonio, LLC
-
Hovedetterforsker:
- Amita Patnaik, MD
-
Ta kontakt med:
- Hector Navarro
- Telefonnummer: 210-593-5700
- E-post: Hector.Navarro@startresearch.com
-
-
Utah
-
West Valley City, Utah, Forente stater, 84119
- Rekruttering
- START Mountain Region, LLC
-
Hovedetterforsker:
- William McKean, MD
-
Ta kontakt med:
- William B McKean
- Telefonnummer: 1 (801) 907-4750
- E-post: info@startresearch.com
-
-
Virginia
-
Fairfax, Virginia, Forente stater, 22031
- Rekruttering
- NEXT Virginia
-
Hovedetterforsker:
- Mohamad Salkeni, MD
-
Ta kontakt med:
- Maybelle De La Rosa
- Telefonnummer: 703-783-4518
- E-post: nxtvir_coordinators@nextoncology.com
-
-
-
-
K'alak'i T'bilisi
-
Batumi, K'alak'i T'bilisi, Georgia, 6000
- Rekruttering
- High Technology Hospital MedCenter Ltd
-
Hovedetterforsker:
- Tamta Makharadze, MD
-
Ta kontakt med:
- Mamuka Sikharulidze
- Telefonnummer: +995 568 999 559
- E-post: sikharulidzemamuka3@gmail.com
-
Tbilisi, K'alak'i T'bilisi, Georgia, 114
- Rekruttering
- Pineo Medical Ecosystem
-
Ta kontakt med:
- Nino Kekenadze
- Telefonnummer: +995 593 660 940
- E-post: Nkekenadze@pineo.ge
-
Hovedetterforsker:
- Mziuri Zakaraia, MD
-
Tbilisi, K'alak'i T'bilisi, Georgia, 112
- Aktiv, ikke rekrutterende
- LLC ARENSIA Exploratory Medicine
-
Tbilisi, K'alak'i T'bilisi, Georgia, 144
- Aktiv, ikke rekrutterende
- Geo Hospitals Multiprofile Medical Center Tbilisi
-
Tbilisi, K'alak'i T'bilisi, Georgia, 186
- Aktiv, ikke rekrutterende
- LLC Caucasus Medical Centre
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Archival Tissue sample for testing
- Part 1A - Participants with advanced or metastatic cancer who have progressed on/after standard of care therapy or are intolerant to additional effective therapies.
- Female participants with cancer considered to be of childbearing potential (or have tubal ligations only) must be willing to undergo medically induced menopause (Parts 2A and B only)
- Female participants of nonchildbearing potential with cancer must meet at least 1 of the following criteria: Age ≥ 60 years or age <60 years with absence of menstruation for at least 12 months, or had prior removal of both ovaries
- Have Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤1.
- Have adequate bone marrow, renal and liver function.
- Life expectancy of >3 months
- Able to safely administer and retain orally administered study treatment
- Able to comply with contraceptive/barrier requirements
Key Exclusion Criteria:
- Known symptomatic brain metastases or leptomeningeal metastasis
- Known primary CNS malignancy and any other malignancies within 2 years prior to the first dose with the exception of adequately treated localized tumor.
- Have impairment of GI function or GI disease that may significantly alter the absorption of IDE574.
- Have active liver or biliary disease.
- Have active, uncontrolled bacterial, fungal, or viral infection
- Have clinically significant cardiac abnormalities and/or blood clotting events within 6 months before the first dose
- If participants had adverse reactions to previous experimental antitumor treatment that have not recovered to Grade ≤ 1
- Prior irradiation to >25% of the bone marrow.
- Known or suspected hypersensitivity to IDE574/excipients or components (Parts 1 & 2) or fulvestrant/excipients or components (Part 2 only)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Monotherapy Dose Escalation (Part 1A)
Participants with the appropriate tumor types will be treated with escalating doses of IDE574 |
IDE574 |
|
Eksperimentell: Monotherapy Dose Expansion (Part 1B)
Participants with advanced or metastatic cancer will be treated using the RDE or MTD of IDE574 |
IDE574 |
|
Eksperimentell: Combination Dose Escalation (Part 2A) IDE574 + Fulvestrant
Participants with advanced or metastatic cancer will be treated with escalating doses of IDE574 in combination with fulvestrant |
IDE574 Fulvestrant Injection |
|
Eksperimentell: Combination Dose Expansion (Part 2B)
Participants with advanced or metastatic cancer will be randomly assigned to doses of IDE574 + Fulvestrant |
IDE574 Fulvestrant Injection |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety and Tolerability of IDE574 in Part 1 A Monotherapy Dose escalation
Tidsramme: Following the first dose of IDE574
|
incidence of DLT; incidence and severity of AEs/serious adverse events (SAEs) graded based on CTCAE V6.0 |
Following the first dose of IDE574
|
|
Safety and Tolerability of IDE574 in Part 1B Monotherapy Dose expansion based on incidence and severity of AEs/SAEs
Tidsramme: total study duration
|
Incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on the ORR per RECIST version 1.1
Tidsramme: total study duration
|
Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on DOR per RECIST version 1.1.
Tidsramme: total study duration
|
Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2A Combination Dose Escalation based on incidence of DLT
Tidsramme: total study duration
|
Incidence of DLT; incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the incidence and severity of AEs/SAEs
Tidsramme: total study duration
|
Incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the ORR per RECIST version 1.1
Tidsramme: total study duration
|
Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on DOR per RECIST version 1.1.
Tidsramme: total study duration
|
Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on the ORR per RECIST version 1.1
Tidsramme: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on DOR per RECIST version 1.1.
Tidsramme: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Clinical Benefit Rate (CBR)
Tidsramme: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Disease control rate
Tidsramme: total study duration
|
total study duration
|
|
Evaluate the pharmacokinetics (PK) of IDE574 in Part 1A Monotherapy Dose Escalation
Tidsramme: total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 1B Monotherapy Dose Expansion
Tidsramme: total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion
Tidsramme: total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion based on DCR for other solid tumor types
Tidsramme: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on ORR per RECIST version 1.1
Tidsramme: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on DOR per RECIST version 1.1
Tidsramme: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on CBR per RECIST version 1.1
Tidsramme: total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 2A Combination Dose Escalation
Tidsramme: total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on CBR per RECIST version 1.1
Tidsramme: total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 2B Combination Dose Expansion
Tidsramme: total study duration
|
total study duration
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- IDE574-001
- 178299 (Annen identifikator: Regulatory Agency Identifier Number (s))
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .